Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Martin Maron, MD
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Alexander Fanaroff, MD
Preventive PCI versus optimal medical therapy only for vulnerable plaques
Marc Bonaca, MD
Promising results for APOC3 ASO in familial chylomicronemia syndrome
Erik Stroes, MD, PhD
Loading...
We’re glad to see you’re enjoying PACE-CME…but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.